Expert Perspectives on Extended Follow-Up Data from ALPINE

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

Related Keywords

Chaitras Ujjani , ,Evolving Treatment Strategies ,Chronic Lymphocytic Leukemia ,Extended Follow Up Data ,Cll ,Btki ,Venetoclax ,Obinituzumab ,Continuous Btki Therapy ,Fixed Duration Therapy ,Tumor Lysis Monitoring ,Ibrutinib ,Acalabrutinib ,Zanubrutinib ,Sequoia ,Elevate Tn ,Mash 2023 ,Alpine ,Elevate Rr ,Aramaic ,Treatment Naïve Cll ,Newly Diagnosed Cll ,Relapsed Cll ,Refractory Cll ,Efficacy ,Safety ,Real World Data ,Treatment Resistance ,Covalent Btki ,Non Covalent Btki ,Captivate ,Flair ,Hypertension ,Atrial Fibrillation ,Ventricular Arrythmia ,Cardiovascular Aes ,Treatment Selection ,Mechanisms Of Resistance ,Pirtobrutinib ,